1. MXenes schematic composition
[14] 2. Schematic preparation methods for MXenes and products prepared by chemical vapor deposition
3. (a) Schematic diagrams of Ti
3C
2 nanoparticles on PTT in 4T1 tumor bearing nude mice
[30] and (b) Nb
2C nanosheets for PTT
in vivo under NIR-I and NIR-II
[28] 4. Schematic diagrams of (a) Ti
3C
2 nanomaterials loaded with DOX for tumor PTT/PDT/CHEMO combined therapy
[29], (b) DOX@Ti
3C
2-SP nanomaterials for tumor PTT/CHEMO combined therapy
[32], and (c) Ti
3C
2@Met@CP nanomaterials for tumor PTT/PDT/CHEMO combined therapy
[57] 5. Schematic illustrations for (a) combined therapy on HCC cells as assisted by DOX@Ti
3C
2@mMSNs-RGD at the cell level
[58], (b) CTAC@Nb2C-MSN-PEG-RGD composite nanomaterials releaseing CTAC under the action of PTT for combined treatment of tumor
[59], (c) AIPH@Nb
2C@Si composite nanomaterials generating free radicals under the action of PTT
[60], and (d) Nb
2C-MSNs-SNO composite nanomaterials releasing NO under the action of PTT for combined treatment of tumor
[61] 6. Schematic diagrams of (a) MnO
x/Ti
3C
2[64], (b) Ta
4C
3-IONP
[62], (c) MIG
[65], (d) GdW
10@Ti
3C
2[66], and (e) Ti
3C
2@Au
[67] composite nanomaterials in tumor theranostics
7. Schematic diagrams of the application of MXenes nanomaterials in (a) biosensing
[81] and (b) bone tissue engineering
[82] Preparation method | Advantages | Disadvantages | Ref. |
---|
HF acid etching | Simple | Using highly corrosive and harmful HF | [11] | Fluoride salt | Milder reaction conditions; Safer than that of HF acid etching | Difficult to prepare nitride MXenes | [36-37] | Molten salt | Preparing nitride MXenes and preparing MXenes through non-MAX materials | Requiring inert protective gas, under high temperature condition | [19,38] | Alkali assisted hydrothermal | Preparing MXenes without fluorine functional groups | High concentration of NaOH, requiring inert protective gas, under high temperature condition | [39] | Chemical vapor deposition | Precise controlling element composition, size and surface groups | Difficult to prepare large-sized MXenes | [41] |
|
Table 1. Summary of preparation methods of MXenes
MXenes material | First
report time
| NIR
range
| Wavelength
/nm
| Extinction coefficient/(L·g-1·cm-1)
| Photothermal conversion efficiency/% | NIR power
/(W·cm-2)
| Irradiation
time /min
| Temperature
range/℃
| Ref. |
---|
Ti3C2 | 2016/10 | NIR-I | 808 | 25.2 | - | 0.8 | 5 | 23.5-60.0 | 54 | Nb2C
| 2017/10 | NIR-I | 808 | 37.6 | 36.5 | 1.5 | 5 | 25.0-60.0 | 28 | NIR-II | 1064 | 35.4 | 46.65 | 1.5 | 5 | 25.0-60.0 | Ta4C3 | 2017/11 | NIR-I | 808 | 8.67 | 34.9 | 2.0 | 5 | 32.5-65.0 | [27] | Ti2C
| 2019/01 | NIR-I | 808 | 7.39 | 87.1 | 2.0 | 2 | 25.5-93.8 | [48] | Mo2C
| 2019/04 | NIR-I | 808 | 18.0 | 24.5 | 1.0 | 10 | 25.0-57.8 | [49] | NIR-II | 1064 | 12.3 | 43.3 | 1.0 | 10 | 25.0-62.3 | V2C
| 2020/01 | NIR-I | 808 | 38.3 | 48.5 | 0.48 | 10 | 24.0-57.9 | [50] | Ti2N
| 2020/11 | NIR-I | 808 | 41.25 | 48.62 | 1.0 | 5 | 25.0-60.0 | [51] | NIR-II | 1064 | 34.92 | 45.51 | 1.0 | 5 | 25.0-60.0 |
|
Table 2. First application of MXenes in PTT on tumor
MXenes | Report time | Cell lines | Treatment
strategy
| Diagnosis
strategy
| Molecule for
targeting
| Ref. |
---|
Ti3C2 | 2016/10 | 4T1 | PTT | - | - | [54] | Ti3C2-SP
| 2016/12 | 4T1 | PTT | - | - | [30] | MnOx/Ti3C2-SP
| 2017/08 | 4T1 | PTT | PA/MR | - | [64] | Nb2C-PVP
| 2017/10 | 4T1 | PTT | PA | - | [28] | Ti3C2 | 2017/10 | HeLa/MCF-7/U251/HEK293 | PTT | PA | - | [68] | Ti3C2-DOX
| 2017/11 | HCT-116 | PTT/PDT/CHEMO | - | HA | [29] | MnOx/Ta4C3-SP
| 2017/11 | 4T1 | PTT | MR/CT/PA | - | [27] | Ta4C3-SP
| 2017/12 | 4T1 | PTT | PA/CT | - | [69] | GdW10@Ti3C2 | 2018/01 | 4T1 | PTT | CT/MR | - | [66] | DOX@Ti3C2-SP
| 2018/02 | 4T1 | PTT/CHEMO | PA | - | [32] | Ta4C3-IONP-SP
| 2018/02 | 4T1 | PTT | CT/MR | - | [62] | DOX@Ti3C2@mMSNs- RGD
| 2018/04 | SMMC-7721 | PTT/CHEMO | - | RGD | [58] | CTAC@Nb2C-MSN-PEG-RGD
| 2018/08 | U87 | PTT/CHEMO | PA | RGD | [59] | Ti3C2@Au
| 2018/12 | 4T1 | PTT/RT | PA/CT | - | [67] | A@Nb2C@Si
| 2019/01 | 4T1 | PTT/CHEMO | PA | - | [60] | Ti2C
| 2019/01 | A375/HaCaT/MCF-7/MCF-10A | PTT | - | - | [48] | Mo2C
| 2019/04 | 4T1 | PTT | - | - | [49] | Mo2C@C
| 2019/04 | HepG2/HUVEC/IOSE80 | PTT/PDT | PA/CT | - | [70] | Au/Ti3C2 | 2019/06 | MCF-7 | PTT | - | - | [71] | Au/Fe3O4/Ti3C2 | 2019/06 | MCF-7 | PTT | - | - | [71] | MIG(Ti3C2-IONP@PEG-GOD)
| 2019/10 | 4T1 | PTT/CHEMO | MR | - | [65] | Nb2C-MSNs-SNO
| 2019/11 | 4T1 | PTT/CHEMO | PA | - | [61] | Ti2N
| 2019/11 | MCF-7/A365/MCF-10A/HaCaT | PDT | - | - | [72] | V2C
| 2020/01 | MCF-7 | PTT | - | - | [50] | TO-MX(Ti3C2/Ti2O3)
| 2020/02 | A375/HaCaT/MCF-7/MCF-10A | PDT | - | - | [73] | PVP/Nb2C
| 2020/04 | 4T1 | PTT | - | - | [74] | Nb2C/zein
| 2020/04 | 4T1 | PTT | - | - | [75] | NMQDs-Ti3C2Tx | 2020/04 | ADSCs/HeLa/MCF-7 | PDT/CHEMO | - | - | [76] | Nb2C/PLL
| 2020/05 | A375/HaCaT | PDT | - | - | [77] | Nb4C3/PLL
| 2020/05 | A375/HaCaT | PDT | - | - | [77] | Ti3C2@Met@CP
| 2020/06 | MDA-MB-231 | PTT/PDT/CHEMO | - | - | [57] | DOX@Ti3C2-CoNWs
| 2020/06 | 4T1 | PTT/CHEMO | - | - | [78] | Ti3C2/CA4@PLEL
| 2020/06 | 4T1/HUVECs | PTT/CHEMO | - | - | [79] | Ti2N
| 2020/11 | 4T1/U87/293T | PTT | PA | - | [51] | MXene(Ti3C2)-DOX
| 2021/01 | HeLa | PTT/PDT/CHEMO | - | - | [80] |
|
Table 3. MXenes for application in tumor theranostics